Traditional approach to cancer drugs

Drugs are developed to inhibit proliferating cells as they dominate genetic signatures of tumors through sheer numbers

Invasive phenotype

Aggressive cancers are difficult to treat due to a subpopulation of stem cell-like invasive cells that cause tumor spread, and are not responsive to treatment (drugs, chemo and radiation therapies)

Using our innovative discovery engine, we are developing small-molecule drugs that target both proliferative and invasive phenotypes, promising a new paradigm for treating aggressive cancers

Groundbreaking discovery engine

Our discovery engine combines a rapid target discovery platform focused on aggressive cancer phenotypes with a breakthrough synthetic biology platform that allows probing of kinases that are otherwise inactive in vitro. This fully integrated discovery engine allows rapid determination of novel genomic drivers of aggressive cancers and novel kinase drugs to target these drivers.
The SIDERA engine integrates two platform technologies, RACE (Rapid Analysis of Cell-phenotype Extremes) and RAKE (Recombinantly Activated Kinase Evaluation), to identify lead compounds that target aggressive subpopulations. Resulting compounds are then taken through lead optimization, followed by xenograft in vivo studies.
Disease targets
Screening with
engineered
phosphoproteins
Validation with
aggressive
subpopulations
1
3
Lead compounds
2
4

Relevant publications by our team

A flexible codon in genomically recoded Escherichia
coli permits programmable protein phosphorylation
 
Nature Communications - Sep 9, 2015
Migration phenotype of brain-cancer cells predicts patient outcomes
 
Cell Reports - June 9, 2016
Genomically recoded organisms expand biological functions
 
Science - Oct 18, 2013
Expanding the genetic code of Escherichia coli with phosphoserine
 
Science - Aug 26, 2011

© 2017 Sidera Medicine LLC